Claims for Patent: 9,487,830

Summary for Patent: 9,487,830

Title:	Determining the replicative history of lymphocytes
Abstract:	The invention relates to the field of immunology and immunodiagnostics. Provided is a method for determining the replicative history of a lymphocyte, preferably a B cell, the method comprising detecting a signal joint nucleotide sequence on an extrachromosomal circular excision product in the lymphocyte, wherein the excision product is deleted from a chromosome to give a chromosomal-coding joint nucleotide sequence, wherein the coding joint is retained in the chromosome, and detecting the coding joint nucleotide sequence in the lymphocyte. Also provided are primers, probes and a control cell for use in a method of the invention. A method provided herein is among others advantageously used to assess recovery of the precursor B-cell compartment, for example, in a patient following bone marrow transplantation
Inventor(s):	van Dongen; Jacobus J. M. (Nieuwerkerk aan den IJssel, NL), Szczepanski; Thomasz (Zabrze, PL)
Assignee:	Erasmus Universiteit Rotterdam (Rotterdam, NL)
Application Number:	11/409,718
Patent Claims:	1. A method of determining the replicative history of a lymphocyte population, comprising: a) obtaining at least one population of lymphocytes; b) assaying the quantity of an extrachromosomally maintained signal joint arising from formation of a chromosomal coding joint in the lymphocyte population; c) assaying the quantity of the chromosomal coding joint in the lymphocyte population d) providing a population of control cells, which cells have been transformed with at least one exogenously introduced nucleic acid encoding a nucleotide sequence of a signal joint and/or at least one exogenously introduced nucleic acid encoding a nucleotide sequence of a coding joint such that said control cells have both a nucleic acid encoding a nucleotide sequence of a signal joint and a nucleic acid encoding a nucleotide sequence of a coding joint, and assaying the quantity of said signal joint nucleotide sequence and said coding joint nucleotide sequence wherein the quantity of said signal joint nucleotide sequence and said coding joint nucleotide sequence provides a control result; and e) determining the replicative history of the lymphocyte population based on a ratio of the quantity of the chromosomal coding joint to the quantity of the extrachromosomally maintained signal joint in the lymphocyte population, wherein the control result is used as a control for the ratio between the chromosomal coding joint and extrachromosomally maintained signal joint. 2. The method of claim 1, wherein the lymphocyte population is a B cell population. 3. The method of claim 2, wherein the B cell population is selected from a group consisting of: a precursor B cell population, a neonatal cord blood B cell population, a childhood peripheral blood B cell population, an adult peripheral blood B cell population, a B cell population obtained from a tonsil, a B cell population obtained from a lymph node, a B cell population obtained from bone marrow, a B cell population obtained from a germinal center, a B cell population obtained from peripheral blood, a virgin B cell population, a memory B cell population, a B cell population with an IgH class switch, and a B cell population without an IgH class switch. 4. The method of claim 2, wherein assaying comprises RQ-PCR analysis. 5. The method of claim 1, wherein the lymphocytes are obtained from a subject who has received a bone marrow transplant. 6. The method of claim 1, wherein the chromosomal coding joint and the extrachromosomally maintained signal joint are formed from an end-stage gene rearrangement. 7. The method of claim 6, wherein the end-stage gene rearrangement is an intron RSS to Kde rearrangement or a VK to Kde rearrangement. 8. The method of claim 6, wherein the end-stage gene rearrangement is an intron RSS to Kde rearrangement rearrangement. 9. The method of claim 8, wherein assaying comprises RQ-PCR analysis. 10. The method of claim 1, wherein the chromosomal coding joint and the extrachromosomally maintained signal joint are formed from a VH to DH rearrangement. 11. The method of claim 1, wherein assaying comprises real-time quantitative (RQ) PCR analysis. 12. The method of claim 11, wherein the RQ-PCR analysis utilizes at least one nucleic acid amplification primer selected from the group consisting of SEQ ID NOs: 1-3, 5-9, 17, 19, and 20. 13. The method of claim 1, wherein at least one exogenously introduced nucleic acid encoding the signal joint nucleotide sequence and at least one exogenously introduced nucleic acid encoding the coding joint nucleotide sequence are stably integrated in the genome of the control cell. 14. The method of claim 1, wherein the signal joint nucleotide sequence and the coding joint nucleotide sequence of the control cells are homologous to a signal joint nucleotide sequence and a coding joint nucleotide sequence formed as the result of an intron-RSS-Kde rearrangement. 15. The method of claim 1, wherein said control cells further comprise a nucleic acid comprising a Kde nucleic acid sequence in germline configuration.

Details for Patent 9,487,830

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-10-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-10-25
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-10-25